L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R,R))-

Neuroendocrine Carcinoma

Novartis Pharmaceuticalsprotein_peptidePhase 2Dormant

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 47/ 100
Competitive Position: 81/ 100

Competitive context

48 Active assets in the Neuroendocrine Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Etoposide National Cancer Institute (NCI)	Phase 2	B
Everolimus AIO-Studien-gGmbH	Phase 2	B
Cis-Diamminedichloroplatinum Ii National Cancer Institute (NCI)	Phase 2	B
Tarlatamab National Cancer Institute (NCI)	Phase 2	B
Pembrolizumab Ochsner Health System	Phase 2	B

View all 50 →

Same molecule, other indications

L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- is also rated in:

esophageal varicesDormant

Indicative · Phase 4

71 / 100

View asset →

diarrheal diseaseDormant

Indicative · Phase 3

71 / 100

View asset →

cirrhosis of liverDormant

Indicative · Phase 4

71 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →